Hero background Hero background

Targeting Disease
at the Nuclear Pore

Discover Now

European Hematology Association 2016

Copenhagen

9-12 June
2016

European Hematology
Association

Copenhagen, 9-12 June 2016

Read More

About art top About art bottom

About Karyopharm

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.

Read more
Publications art top Publications art bottom

Publications

Scientific Papers, Posters and Presentations on Karyopharm pipeline compounds

Papers

Novel Small Molecule XPO1/CRM1

Yang J (1), Bill MA (1), Young GS (2), La Perle K (3), Landesman

Selective inhibitors of nuclear

Mendonca J (1), Sharma A (1), Kim HS (2), Hammers H (2), Meeker A

Posters & Presentations

Phase I Study of Selinexor, a Selective

Melphalan and XPO1 Inhibition are

+ Visit Archive
Pipeline widget background Pipeline widget background

Pipeline

Our Drug Candidates: SINE™ Compounds and PAK4/NAMPT Inhibitors

View Pipeline

Stock Quote (KPTI)

Investor Information
Stock Quote loader

Service temporary unavailable

Previous Close
Open
Volume
Exchange
Day High
Day Low
52-Week High
52-Week Low